Wegovy Manufacturing Issues Continue To Hamper Novo Nordisk

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

Danish pharma says it will not market the weight-loss formulation of semaglutide until manufacturing can meet demand. Novo has seen significant growth in GLP-1 franchise in both diabetes and obesity.

Novo Nordisk
Novo Nordisk continues to win GLP-1 market share in diabetes

Novo Nordisk A/S disappointed analysts during its 3 August second quarter earnings call with the news that full supply of its weight-loss drug Wegovy (semaglutide) is now likely toward the end of 2022, rather than during the second half of the year as previously indicated. Combined with news that the SELECT cardiovascular outcomes trial of the drug will not have an interim readout prior to its expected conclusion in mid-2023, the news overshadowed a nonetheless strong growth quarter for the Copenhagen-based firm – including stellar sales for the semaglutide franchise.

Since its launch in mid-2021, sales of Wegovy, a formulation of the GLP-1 analog also contained in the type 2...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.